Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Stefanie Schalm"'
Autor:
Stefanie Schalm, Yogesh Chutake, Susanne Breitkopf, Michele Mayo, Nancy Dumont, Dapeng Chen, Vaishali Dixit, Rahul Karnik, Alice Mcdonald, Jessica Filiatrault, William Proctor, Frank Qi, Kan-Nian Hu, Matt Weiss, Ashwin Gollerkeri, Kirti Sharma, Joseph D Growney, Juliet Williams
Publikováno v:
HemaSphere, Vol 7, p e9022892 (2023)
Externí odkaz:
https://doaj.org/article/fca8737a0dd94eb586ac0ead969eb970
Autor:
Xiaofang Wang, Li Jiang, Ka Thao, Caroline R. Sussman, Timothy LaBranche, Michael Palmer, Peter C. Harris, G. Stanley McKnight, Klaus P. Hoeflich, Stefanie Schalm, Vicente E. Torres
Publikováno v:
J Am Soc Nephrol
BACKGROUND: Upregulation of cAMP-dependent and cAMP-independent PKA signaling is thought to promote cystogenesis in polycystic kidney disease (PKD). PKA-I regulatory subunit RIα is increased in kidneys of orthologous mouse models. Kidney-specific kn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d80c427f549873fee3233309ffbae68
https://doi.org/10.1681/asn.2021081125
https://doi.org/10.1681/asn.2021081125
Autor:
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Ayşegül Özen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen
Publikováno v:
Journal of medicinal chemistry. 65(14)
While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small-cell lung cancer (NSCLC), most patients will eventually develop resistance to TK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a80b3cdcda4b5b59447b540cafce20
https://pubmed.ncbi.nlm.nih.gov/35838760
https://pubmed.ncbi.nlm.nih.gov/35838760
Autor:
Luz Tavera, Stefanie Schalm, John Campbell, Jian Guo, Clare Medendorp, Maxine Chen, Faris Albayya, Tom Dineen, Zhuo Zhang, Maria Iliou, Ebby Job, Nisha Perez, Yoav Timsit, Scott Wardwell, Katie McGinn, Richard Woessner, Chiara Conti
Publikováno v:
Cancer Research. 82:3328-3328
BACKGROUND: Lung cancer is the leading cause of cancer death globally. EGFR mutations are the most common genomic drivers of non-small cell lung cancer (NSCLC), occurring in ~17% and up to 50% of Caucasian and Asian patients, respectively, with exon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2436066723bb6ef5f79b0acdea521bbe
https://doi.org/10.1158/1538-7445.am2022-3328
https://doi.org/10.1158/1538-7445.am2022-3328
Autor:
Yogesh Chutake, Michele Mayo, Dapeng Chen, Bradley Enerson, Patricia Cho, Jessica Filiatrault, Crystal Brown, Michael Placke, Madison Adams, Rahul Karnik, James Shaw, Yatao Shi, Dirk Walther, Alice McDonald, Frank Qi, Phillip Liu, Joseph D. Growney, Kirti Sharma, Duncan Walker, Stefanie Schalm, Juliet Williams, Matthew Weiss
Publikováno v:
Cancer Research. 82:3934-3934
Background: The murine double minute 2 (MDM2) oncoprotein is a key E3 ubiquitin ligase that degrades the tumor-suppressor p53. Reversible SMIs of the MDM2/p53 interaction have been developed to stabilize p53 and to induce apoptosis in wildtype p53 tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c678c38306cd933aecd0f5645a29b016
https://doi.org/10.1158/1538-7445.am2022-3934
https://doi.org/10.1158/1538-7445.am2022-3934
Autor:
Faris Albayya, Doug Wilson, Rich Woessner, Sun Min Lim, Zhuo Zhang, Klaus P. Hoeflich, Byoung Chul Cho, John Hsieh, John Campbell, Meredith Eno, Chae Won Park, Faith Stevison, Tom Dineen, Marion Dorsch, Caitlin Utt, Nicolas Lamontagne, Stefanie Schalm
Publikováno v:
Cancer Research. 81:1467-1467
Background: EGFR-activating mutations (L858R and ex19del) are major drivers (15-47%) of lung adenocarcinoma. EGFR TKI development has changed the treatment paradigm for EGFR-mutant (EGFR+) NSCLC. However, tumors often develop acquired resistance muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::958f36d6ca1d0005f999de30ac6e556b
https://doi.org/10.1158/1538-7445.am2021-1467
https://doi.org/10.1158/1538-7445.am2021-1467
Autor:
Darshan S. Sappal, Vivek Kadambi, Riadh Lobbardi, Joseph L. Kim, Adam Shutes, Michael Palmer, Nicolas Stransky, Robert M. Campbell, Richard Woessner, Timothy LaBranche, Klaus P. Hoeflich, Neil Bifulco, Andrew P. Garner, Grace O. Silva, Erin O’Hearn, Kevin J. Wilson, Timothy J. Guzi, Stefanie Schalm, Marion Dorsch, Lucian DiPietro, Stephen D. Miller, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 18:B127-B127
Introduction: Fibrolamellar Carcinoma (FLC) is a rare primary liver malignancy, affecting children and young adults without chronic liver disease. FLC tumors are largely resistant to chemotherapy, making the identification of effective treatment opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49d5047a5f77900a009043aa6b75a1f6
https://doi.org/10.1158/1535-7163.targ-19-b127
https://doi.org/10.1158/1535-7163.targ-19-b127
Autor:
Timothy A. Chan, Kaiko Kunii, Thomas G. Graeber, Alicia Pedraza, Barbara Oldrini, Owen Clark, Jennifer Tsoi, Stefanie Schalm, Cameron Brennan, Fang Wang, Yue Chen, Shinsan M. Su, Hua Yang, Alexandra Miller, Scott A. Biller, Sevin Turcan, Lee Silverman, Carl Campos, Marc K. Rosenblum, Wei Liu, Andrew Kernytsky, Evangelia Komisopoulou, Ingo K. Mellinghoff, Katharine E. Yen, Christian Grommes, Nicolaos Palaskas, Dan Rohle, Janeta Popovici-Muller
Publikováno v:
Science. 340:626-630
IDHology Among the most exciting drug targets to emerge from cancer genome sequencing projects are two related metabolic enzymes, isocitrate dehydrogenases 1 and 2 (IDH1, IDH2). Mutations in the IDH1 and IDH2 genes are common in certain types of huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f402b408f5c49abea600bf33f830a56c
https://doi.org/10.1126/science.1236062
https://doi.org/10.1126/science.1236062
Autor:
Shunqi Yan, Scott A. Biller, Fang Wang, David P. Schenkein, Marion Dorsch, Shinsan M. Su, Jeffrey O. Saunders, Jeremy Travins, Wentao Wei, Kimberly Straley, Wei Liu, Stefan Gross, Camelia Gliser, Lenny Dang, Elena Mylonas, Hua Yang, Sam Agresta, Erica Hansen, Véronique Saada, Stéphane de Botton, Byron DeLaBarre, Katharine E. Yen, Janeta Popovici-Muller, Stuart Murray, Erin Artin, Stefanie Schalm, Cyril Quivoron, Andrew Kernytsky, Virginie Penard-Lacronique, Yi Gao, Francesco G. Salituro
Publikováno v:
Science. 340:622-626
IDHology Among the most exciting drug targets to emerge from cancer genome sequencing projects are two related metabolic enzymes, isocitrate dehydrogenases 1 and 2 (IDH1, IDH2). Mutations in the IDH1 and IDH2 genes are common in certain types of huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29fb3aa7882e5c926f2b401241cd644f
https://doi.org/10.1126/science.1234769
https://doi.org/10.1126/science.1234769
Autor:
Hua Yang, Stefanie Schalm, David P. Schenkein, Shinsan M. Su, Fang Wang, Kimberly Straley, Katharine E. Yen, Andrew Kernytsky, Wei Liu, Camelia Gliser, Marion Dorsch, Erica Hansen, Scott A. Biller, Jeremy Travins, Sam Agresta, Stuart Murray
Mutations of IDH1 and IDH2, which produce the oncometabolite 2-hydroxyglutarate (2HG), have been identified in several tumors, including acute myeloid leukemia. Recent studies have shown that expression of the IDH mutant enzymes results in high level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf0d21f3602f26e91fe0eec93a61d4aa
https://europepmc.org/articles/PMC4295919/
https://europepmc.org/articles/PMC4295919/
